2288312
Last Update Posted: 2015-01-08
Recruiting has ended
All Genders accepted | 18 Years-55 Years |
18 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate
Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.
Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects. The study consisted of 3 periods separated by a washout of 7 days or more between doses. Subjects received a single oral 800 mg dose of eslicarbazepine acetate following a standard meal in one period, and following at least 10 hours of fasting in two periods.
Eligibility
Relevant conditions:
Epilepsy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov